GO
Loading...

Endo Health Solutions Inc

More

  • March 6- Endo International Plc said the U.S. Food and Drug Administration approved its thrice-rejected testosterone replacement therapy, Aveed, to treat male hypogonadism.

  • Last month, the FDA issued an alert and said it was investigating the risk of stroke, heart attack and death in men taking testosterone drugs based on the recent publication of two studies that suggested increased cardiac risk. But the FDA said it had not concluded that testosterone does, in fact, increase heart problems.

  • Testosterone therapy is approved by the FDA for men who lack or have low testosterone in conjunction with an associated medical condition, such as a genetic failure of the testicles to produce testosterone.

  • WASHINGTON, Jan 31- The U.S. Food and Drug Administration said on Friday it is investigating the risk of stroke, heart attack and death in men taking prescription testosterone drugs.

  • Jan 21- NuPathe Inc said it terminated its takeover deal with Endo Health Solutions Inc and accepted an offer from Israel's Teva Pharmaceutical Industries Ltd. Teva offered to buy the neurology drugs maker on Jan. 8 for $114 million plus milestone payments related to its Zecuity migraine treatment.

  • UPDATE 1-NuPathe gets takeover offer from Israel's Teva Wednesday, 8 Jan 2014 | 9:11 AM ET

    Jan 8- Israel's Teva Pharmaceutical Industries Ltd offered to buy U.S. neurology drugs maker NuPathe Inc for $114 million plus milestone payments related to NuPathe's Zecuity migraine treatment.

  • NuPathe gets takeover offer from Israel's Teva Wednesday, 8 Jan 2014 | 8:04 AM ET

    Jan 8- NuPathe Inc said it received a buyout offer from Israel's Teva Pharmaceutical Industries Ltd for $114 million plus milestone payments related to NuPathe's Zecuity migraine treatment.

  • Endo Health to acquire Nupathe for $105 million Monday, 16 Dec 2013 | 7:56 AM ET

    Dec 16- Specialty pharmaceutical company Endo Health Solutions Inc said it would buy NuPathe Inc for about $105 million to gain access to NuPathe's migraine treatment, Zecuity. NuPathe shareholders will get $2.85 per share, a premium of 24 percent to the stock's Friday close. NuPathe shares jumped nearly 61 percent to $3.70 in trading before the bell.

  • Nov 5- U.S.-based specialty pharmaceutical company Endo Health Solutions Inc will buy Canadian peer Paladin Labs Inc to expand its presence in Canada and emerging markets, as generic competition for its top drugs squeeze sales.

  • Nov 5- Specialty pharmaceutical company Endo Health Solutions Inc said it would acquire Canadian peer Paladin Labs Inc for about $1.6 billion to expand its presence in Canada and emerging markets.

  • Check out which companies are making headlines after the bell Wednesday:

  • After-Hours Buzz: GPS, CRM, GRPN & More Thursday, 28 Feb 2013 | 3:40 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • After-Hours Buzz: CSTR, PRGS & More Thursday, 3 Jan 2013 | 4:39 PM ET

    Check out which companies are making headlines after the bell Thursday:

  • After-Hours Buzz: Juniper, Boston Beer & More Wednesday, 12 Dec 2012 | 5:42 PM ET

    Check out which companies are making headlines after the bell Wednesday.

  • Shares of Samsung Electronics, which have surged almost 35 percent since the start of the year, closed at an all-time high on Thursday boosted by expectations that its smartphone business will continue to drive strong profit growth.

  • Here Are Small Cap Values: Gabelli Wednesday, 21 Nov 2012 | 1:39 PM ET

    With bigger companies looking to grow, many may look to acquire smaller firms. That’s one of the reasons Mario Gabelli, chairman of Gamco Investors, sees opportunity in small-cap equities.

  • Oct 11- Endo Health Solutions Inc:. *FDA- became aware of cases of a serious blood disorder in individuals abusing. *FDA says the disorder related to Endo's Opana ER resulted in kidney failure.

  • Opana, a powerful opioid painkiller containing oxymorphone, is produced by Endo Pharmaceuticals. The blood disorder, thrombotic thrombocytopenic purpura, resulted in kidney failure requiring dialysis in some cases and at least one death, the Food and Drug Administration said.

  • Abuse of painkiller Opana can cause blood disorder-US FDA Thursday, 11 Oct 2012 | 12:12 AM ET

    Opana is produced by Endo Pharmaceuticals. The blood disorder, thrombotic thrombocytopenic purpura, resulted in kidney failure requiring dialysis in some cases, and at least one death, the Food and Drug Administration said. The FDA said problems appear to occur with Opana ER only when it is abused and injected intravenously.

  • Oct 9- Endo Health Solutions Inc:. Reuters Station users, click. 1568. Reuters Station users, click. 4899.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.